Department of Molecular and Integrative Physiology, University of Michigan, 7220 MSRB III, 1150 W Medical Center Drive, SPC 0644, Ann Arbor, MI, 48109-5853, USA.
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Pflugers Arch. 2019 May;471(5):781-793. doi: 10.1007/s00424-018-2226-9. Epub 2018 Nov 20.
Mutations in cardiac myosin binding protein C (MYBPC3) represent the most frequent cause of familial hypertrophic cardiomyopathy (HCM), making up approximately 50% of identified HCM mutations. MYBPC3 is distinct among other sarcomere genes associated with HCM in that truncating mutations make up the vast majority, whereas nontruncating mutations predominant in other sarcomere genes. Several studies using myocardial tissue from HCM patients have found reduced abundance of wild-type MYBPC3 compared to control hearts, suggesting haploinsufficiency of full-length MYBPC3. Further, decreased mutant versus wild-type mRNA and lack of truncated mutant MYBPC3 protein has been demonstrated, highlighting the presence of allelic imbalance. In this review, we will begin by introducing allelic imbalance and haploinsufficiency, highlighting the broad role each plays within the spectrum of human disease. We will subsequently focus on the roles allelic imbalance and haploinsufficiency play within MYBPC3-linked HCM. Finally, we will explore the implications of these findings on future directions of HCM research. An improved understanding of allelic imbalance and haploinsufficiency may help us better understand genotype-phenotype relationships in HCM and develop novel targeted therapies, providing exciting future research opportunities.
肌球蛋白结合蛋白 C(MYBPC3)基因突变是家族性肥厚型心肌病(HCM)最常见的原因,约占已确定的 HCM 基因突变的 50%。与其他与 HCM 相关的肌节基因不同,MYBPC3 中的截断突变占绝大多数,而非截断突变在其他肌节基因中占主导地位。几项使用 HCM 患者心肌组织的研究发现,与对照心脏相比,野生型 MYBPC3 的丰度降低,提示全长 MYBPC3 的杂合不足。此外,已经证明突变型与野生型 mRNA 的减少以及截断型突变 MYBPC3 蛋白的缺乏,突出了等位基因失衡的存在。在这篇综述中,我们将首先介绍等位基因失衡和杂合不足,强调它们在人类疾病谱中各自的广泛作用。随后,我们将重点关注等位基因失衡和杂合不足在 MYBPC3 相关 HCM 中的作用。最后,我们将探讨这些发现对 HCM 研究未来方向的影响。对等位基因失衡和杂合不足的更好理解可能有助于我们更好地理解 HCM 中的基因型-表型关系,并开发新的靶向治疗方法,为未来的研究提供令人兴奋的机会。